15-year study finds treatment gaps exist for patients with peripheral arterial disease

November 17, 2019

Peripheral arterial disease (PAD) is a progressive and life-threatening form of atherosclerosis that narrows the arteries serving the legs, arms, chest, and abdominal organs. It affects more than 8.5 million people in the United States, including 10 to 20 percent of individuals over 60 years old.

Outcomes of PAD patients are worse than those with coronary disease or cerebrovascular disease, emphasizing the importance of attention to their treatment.Like other kinds of atherosclerotic cardiovascular diseases, it should be treated with high-intensity doses of statins.

However, a new 15-year study by researchers at the Intermountain Healthcare Heart Institute in Salt Lake City found that PAD patients may not be prescribed these life-saving medications at the same rate as for other atherosclerotic conditions, such as heart attack or stroke.

"As a profession we focus so much on coronary disease that we may be not be optimally treating patients with PAD, especially when it comes to statin prescription," said Jeffrey L. Anderson, principal investigator of the study and distinguished clinical and research physician at the Intermountain Healthcare Heart Institute. "However, we found that over time, statin prescription rates across our healthcare system have increased for PAD patients, and with it, PAD patient outcomes have improved. Despite this, there remains a significant treatment gap, so much more progress is needed."

In the study, researchers identified 4,333 patients who had a first encounter with PAD (idisease in the aorta and lower extremities) between January 1, 1999 and December 31, 2013, and survived that event.

They then were followed for at least three years or until their death. Overall, statin prescription was associated with a reduced 3-year rate of subsequent heart attack, stroke, or death, from 23.5% to 18.9%, and it was only 14.3% if the prescription was for a high-intensity statin. Unfortunately, only one-third of patients overall had been prescribed a statin at discharge after their PAD event, and only 11% were prescribed a high-intensity statin.

The Intermountain researchers then gave attention to the treatment trend over 15 years. From 1999 through 2013, a statin prescription increased in five-year increments from 17% to 37% to 48%, indicating steady progress toward the 100% ultimate treatment goal. However, the most recent value of 48% for PAD still lags significantly behind values of 74% for cerebrovascular disease (e.g., stroke) patients and 93% for coronary disease (e.g., heart attack) patients.

Findings from the study will be presented at the 2019 American Heart Association Scientific Sessions Philadelphia on Nov. 17, 2019.

Dr. Anderson noted the favorable progress in PAD treatment, but he highlighted the remaining large treatment gap when compared to coronary and stroke patients, showing that more work needs to be done in statin prescribing for patients with PAD.

"We're doing much better in terms of treating these patients with statins, but there's still a need for more attention to this group," he said. "More than 90 percent of our heart attack patients are prescribed statins. We need to keep focusing on PAD patients to get them to the right physicians who are fully aware of the need to treat them as high-risk patients and to get their statin percentages also up into the mid-90s. These patients represent the highest risk atherosclerosis group, but they also are the group that stands to benefit the most from statin therapy."
Other members of the research team included: Kirk U. Knowlton, Heidi T. May, Tami L. Bair, Viet Le, Donald L. Lappe, and Joseph B. Muhlestein.

Intermountain Medical Center

Related Heart Attack Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

Muscle protein abundant in the heart plays key role in blood clotting during heart attack
A prevalent heart protein known as cardiac myosin, which is released into the body when a person suffers a heart attack, can cause blood to thicken or clot--worsening damage to heart tissue, a new study shows.

New target identified for repairing the heart after heart attack
An immune cell is shown for the first time to be involved in creating the scar that repairs the heart after damage.

Heart cells respond to heart attack and increase the chance of survival
The heart of humans and mice does not completely recover after a heart attack.

A simple method to improve heart-attack repair using stem cell-derived heart muscle cells
The heart cannot regenerate muscle after a heart attack, and this can lead to lethal heart failure.

Mount Sinai discovers placental stem cells that can regenerate heart after heart attack
Study identifies new stem cell type that can significantly improve cardiac function.

Fixing a broken heart: Exploring new ways to heal damage after a heart attack
The days immediately following a heart attack are critical for survivors' longevity and long-term healing of tissue.

Heart patch could limit muscle damage in heart attack aftermath
Guided by computer simulations, an international team of researchers has developed an adhesive patch that can provide support for damaged heart tissue, potentially reducing the stretching of heart muscle that's common after a heart attack.

How the heart sends an SOS signal to bone marrow cells after a heart attack
Exosomes are key to the SOS signal that the heart muscle sends out after a heart attack.

Read More: Heart Attack News and Heart Attack Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.